H A W M Tiddens
Overview
Explore the profile of H A W M Tiddens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zwitserloot A, Aziz S, Chen Y, Bannier M, Janssens H, Merkus P, et al.
Pediatr Pulmonol
. 2025 Jan;
60(1):e27473.
PMID: 39785291
Introduction: Lumacaftor/ivacaftor (lum/iva) was introduced in the Netherlands in 2017. We investigated 1-year efficacy of lum/iva on lung function and small airway and structural lung disease evaluated by multiple breath...
2.
Papp D, Elders B, Wielopolski P, Kotek G, Vogel M, Tiddens H, et al.
Clin Radiol
. 2023 Feb;
78(4):e319-e327.
PMID: 36746723
Aim: To evaluate image quality acquired at lung imaging using magnetic resonance imaging (MRI) sequences using short and ultra-short (UTE) echo times (TEs) with different acquisition strategies (breath-hold, prospective, and...
3.
Harlaar L, Ciet P, van der Ploeg A, Brusse E, van der Beek N, Wielopolski P, et al.
Neuromuscul Disord
. 2018 Feb;
28(3):246-256.
PMID: 29398294
Respiratory muscle weakness frequently occurs in patients with neuromuscular disease. Measuring respiratory function with standard pulmonary function tests provides information about the contribution of all respiratory muscles, the lungs and...
4.
van Velzen A, Bos A, Touw D, Tiddens H, Heijerman H, Janssens H
J Aerosol Med Pulm Drug Deliv
. 2015 Dec;
29(3):273-80.
PMID: 26716357
Background: Better treatment outcomes in cystic fibrosis (CF) may be expected by changing standard twice daily (BID) tobramycin inhalation with the conventional nebulizer to once daily (OD) inhalation at double...
5.
Kurbatova P, Bessonov N, Volpert V, Tiddens H, Cornu C, Nony P, et al.
J Theor Biol
. 2015 Mar;
372:81-8.
PMID: 25746843
Mucus clearance is a primary innate defense mechanism in the human airways. Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding the cystic fibrosis transmembrane...
6.
Tiddens H, De Boeck K, Clancy J, Fayon M, H G M A, Bresnik M, et al.
J Cyst Fibros
. 2014 Aug;
14(1):111-9.
PMID: 25091537
Background: Consensus guidelines recommend early treatment to eradicate newly acquired Pseudomonas aeruginosa (Pa) infection in cystic fibrosis (CF) patients although there is no single preferred regimen. Aztreonam for inhalation solution...
7.
Bakker E, Volpi S, Salonini E, Mullinger B, Kroneberg P, Bakker M, et al.
Pediatr Pulmonol
. 2013 Aug;
49(2):154-61.
PMID: 23913868
Introduction: Small airway obstruction is important in the pathophysiology of cystic fibrosis (CF) lung disease. Additionally, many CF patients lose lung function in the long term as a result of...
8.
Bakker E, van der Meijden J, Nieuwhof E, Hop W, Tiddens H
J Cyst Fibros
. 2012 Jan;
11(3):223-30.
PMID: 22265603
Background: Accurate assessment of pulmonary status in young children with cystic fibrosis (CF) requires sensitive and objective monitoring techniques. Objectives: This study aimed to evaluate the feasibility of lung clearance...
9.
Bakker E, Volpi S, Salonini E, van der Wiel-Kooij E, Sintnicolaas C, Hop W, et al.
Eur Respir J
. 2011 Jul;
38(6):1328-35.
PMID: 21737560
Better treatment of obstructed small airways is needed in cystic fibrosis. This study investigated whether efficient deposition of dornase alfa in the small airways improves small airway obstruction. In a...
10.
de Wit M, Tiddens H, de Coo I, Mancini G
Eur J Med Genet
. 2011 Jan;
54(3):299-300.
PMID: 21194575
Recently in this journal, Masurel-Paulet et al. reported the association between pulmonary disease and a mutation in X-linked FLNA in a male patient. We confirm this association in a female...